We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Diagnostic Panel Used for Pediatric Musculoskeletal Infections

By LabMedica International staff writers
Posted on 31 Jul 2019
The findings from a retrospective analysis suggested that the use of a rapid musculoskeletal diagnostic panel, or MDP, could have shortened the time it took to identify the cause of infection, provide appropriate antibiotics and reduce the length of stay for children in hospital.

The MDP, which was recently validated in another study, combined three separate tests: the Xpert MRSA/Staphylococcus aureus skin and soft tissue infection (SA SSTI) assay, a polymerase chain reaction (PCR) assays for ermA, ermB and ermC genes to determine clindamycin resistance; and a Kingella kingae PCR assay to identify the rtxA gene. More...
Results from the Xpert MRSA/SA SSTI assay were available within three hours, and results for the PCR assays were available by 1400 hours the following calendar day.

Scientists at the Children’s Hospital Colorado (Aurora, CO, USA) included in a study 53 children aged six months to 18 years who were admitted to the hospital with symptoms persisting for less than two weeks, had bone or joint specimens collected and were administered antibiotic therapy, excluding perioperative antibiotics. The investigators identified pathogens in 69.8% of patients (37/53) who underwent standard culturing techniques and in 13 patients (16%) who had a blood culture performed. The most commonly identified pathogen was S. aureus (47.2%), and methicillin-resistant S. aureus (MRSA) was identified in 16% of these patients. Two patients had clindamycin-resistant S. aureus, and one patient had a K. kingae infection.

The MDP identified most children with culture-confirmed S. aureus infection (88%), with three patients having MRSA. When cultured, all three patients were confirmed to have MRSA. Although the MDP identified three isolates as clindamycin resistant, culture showed that one of these isolates was clindamycin susceptible. The results showed that MDP would have saved seven hours to pathogen identification (45.6 hours; interquartile range [IQR] = 23-62) compared with standard microbiology culture techniques (52.5 hours; IQR = 36.1-65.6). Additionally, use of the MDP would have improved the time to definitive antibiotic therapy by nearly 22 hours and reduced the hospital length of stay by a median of 26.4 hours.

The authors noted that cost is an important factor when considering a new diagnostic tool like the MDA. Theoretically, the decrease in length of stay would justify its expense. Justin B. Searns, MD, a hospitalist and first author of the study, said, “No approved rapid diagnostic platforms currently exist for bone and joint specimens from pediatric patients with acute musculoskeletal infection.” The study was published on June 13, 2019, in the Journal of The Pediatric Infectious Disease Society.

Related Links:
Children’s Hospital Colorado


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Gastrointestinal Panel
Xpert® GI Panel
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.